Zurn Elkay Q3 sales rise 11% to $455 million; raises 2025 EBITDA outlook
Zurn Elkay reported third-quarter 2025 net sales of $455 million, up 11% from $410 million a year earlier, and GAAP diluted EPS from continuing operations of $0.35 versus $0.25. The company raised its full-year 2025 adjusted EBITDA outlook to $437 million to $440 million from $420 million to $430 million, and also raised its dividend 22% and its share repurchase authorization to $500 million, which points to higher earnings and more cash returned to shareholders.
Key points
- Q3 net sales $455 million vs. $410 million a year earlier (+11%); adjusted EPS $0.43 vs. $0.34 (+26%)
- Q3 adjusted EBITDA $122 million (26.8% of net sales) vs. $105 million (25.6%)
- Full-year 2025 adjusted EBITDA outlook raised to $437 million to $440 million from $420 million to $430 million
- Annual dividend increased 22% to $0.44 per share; share repurchase authorization increased to $500 million
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.